Profile: Sunesis Pharmaceuticals Inc (SNSS.O)
2 Oct 2015
Sunesis Pharmaceuticals, Inc., incorporated on February 10, 1998, is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company's program is QINPREZOTM (vosaroxin), which is its product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD), which is a class of compounds that has not been used previously for the treatment of cancer.
Vosaroxin is an AQD, which is used for the treatment of cancer. Preclinical data demonstrate that vosaroxin both intercalates deoxyribonucleic acid (DNA) and inhibits topoisomerase II, which is an enzyme for cell replication, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. The Company licensed worldwide development and commercialization rights to vosaroxin from Sumitomo Dainippon Pharma Co., Ltd.
In October 2014, the Company announced the results of a Phase III, multi-national, randomized, double-blind, placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial, which enrolled 711 adult patients, was designed to evaluate the effect of vosaroxin in combination with cytarabine, a used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine. The trial was conducted at 124 study sites in the United States, Canada, Europe, South Korea, Australia and New Zealand.
The Company completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. Three dosing levels in two treatment schedules were studied and -tumor activity was observed across all doses. For patients on dosing levels of 48, 60 and 75 milligrams (mg), the overall response rate (ORR), was 11%, 11% and 9%, respectively; disease control, defined as stable disease for 12 weeks or more, was 46%, 46% and 51%, respectively, and the median progression-free survival (PFS) was 83, 61 and 103 days, respectively. The Company conducted two Phase I clinical trials to evaluate different dosing schedules of vosaroxin in patients with advanced solid tumors. The Company also conducted two Phase II trials in non-small cell lung cancer and small cell lung cancer.
MLN2480 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. The Phase I, multicenter, open-label, dose escalation study was conducted in two stages: dose escalation and cohort expansion.
SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). BTK mediates signaling through the B-cell receptor (BCR), which is critical for adhesion, migration, proliferation and survival of normal and malignant B-lineage lymphoid cells. The rights to develop SNS-062 for oncology indications were in-licensed from Biogen Idec.
SNS-229 and SNS-510
PDK1 is a kinase and mediator of PI3K/AKT signaling, which is a pathway involved in cell growth, differentiation, survival and migration. PDK1 inhibitors have effects on survival and invasion signaling and are active in both hematologic and solid tumor malignancies. The Company has taken a series of PDK1 inhibitors with antitumor activity in vitro and in vivo into preclinical development.
Sunesis Pharmaceuticals Inc
395 Oyster Point Boulevard
SOUTH SAN FRANCISCO CA 94080